Hantavirus Cure Delayed: Funding Fails Scientists

A potential treatment for hantavirus, developed by a Chilean research team, has been stalled due to a lack of funding. By 2016, scientists had successfully created antibodies capable of neutralizing the virus, showing promise in animal trials. However, the necessary investment of approximately $7 million for human trials was unattainable, with progress further hampered by the COVID-19 pandemic shifting global resources.

The Andes virus strain, the only known hantavirus to transmit person-to-person, has recently garnered international concern following an outbreak linked to a cruise ship departing from Argentina. This event underscored the ongoing public health threat posed by the virus, particularly in regions like Chile and southern Argentina.

While other scientists, such as Kartik Chandran at Albert Einstein College of Medicine, are also advancing antibody treatments and have an option ready for human trials, the path to widespread availability for hantavirus remains challenging. Clinical trials are often difficult to conduct due to the rarity of cases, a predicament faced by researchers working on various diseases globally.

The Chilean lab's experience is not unique, as many scientific endeavors faced similar funding obstacles and resource reallocations during the pandemic. Despite reaching milestones like orphan drug status for one antibody by 2021, the human trials remain on hold, emphasizing the critical role of financial support in translating scientific breakthroughs into life-saving medical interventions.